Advanced search
Publication Cover
Emerging Microbes & Infections Volume 12, 2023 - Issue 1
Submit an article Journal homepage
2,495
Views
7
CrossRef citations to date
0
Altmetric
Coronaviruses

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors

Shuai Xiaa Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Lijue Wanga Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Fanke Jiaoa Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Xueying Yub Department of Clinical Laboratory, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Wei Xua Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Ziqi Huanga Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Xicheng Lia Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Qian Wanga Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Yun Zhuc National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaView further author information
,
Qiuhong Manb Department of Clinical Laboratory, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Shibo Jianga Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8283-7135View further author information
ORCID Icon &
Lu Lua Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2255-0391View further author information
ORCID Icon show all
Article: 2178241 | Received 20 Nov 2022, Accepted 04 Feb 2023, Published online: 23 Feb 2023

References

  • WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
  • Karthik Gangavarapu AAL, Mullen J, Alkuzweny M, et al. BA.1 Lineage Report. Available from: https://outbreak.info/situation-reports?pango = BA.1.
  • Rahman S, Hossain MJ, Nahar Z, et al. Emerging SARS-CoV-2 variants and subvariants: challenges and opportunities in the context of COVID-19 pandemic. Environ Health Insights. 2022;16:11786302221129396. doi:10.1177/11786302221129396.
  • Xia S, Wang L, Zhu Y, et al. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduct Target Ther. 2022;7(1):241), doi:10.1038/s41392-022-01105-9.
  • Saito A, Tamura T, Zahradnik J, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe. 2022;30(11):1540–1555.e15. doi:10.1016/j.chom.2022.10.003.
  • Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.4.6. N Engl J Med. 2022;387(20):1904–1906. doi:10.1056/NEJMc2212117.
  • Qu P, Evans JP, Faraone J, et al. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. bioRxiv. 2022;2022.10.19.512891.
  • Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28(9):1785–1790. doi:10.1038/s41591-022-01911-2.
  • Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602. doi:10.1038/s41586-022-04980-y.
  • Hansen CH, Friis NU, Bager P, et al. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark. Lancet Infect Dis. 2022, S1473-3099(22)00595-3.
  • Rocheleau L, Laroche G, Fu K, et al. Identification of a high-frequency intrahost SARS-CoV-2 spike variant with enhanced cytopathic and fusogenic effects. mBio. 2021;12:e0078821.
  • Saito A, Irie T, Suzuki R, et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 delta P681R mutation. Nature. 2022;602(7896):300–306. doi:10.1038/s41586-021-04266-9.
  • Meng B, Abdullahi A, Ferreira I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–714. doi:10.1038/s41586-022-04474-x.
  • Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067), doi:10.1038/ncomms4067.
  • Xia S, Yan L, Xu W, et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019;5:eaav4580), doi:10.1126/sciadv.aav4580.
  • Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30:343–355. doi:10.1038/s41422-020-0305-x.
  • Xia S, Lan Q, Zhu Y, et al. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct Target Ther. 2021;6:288), doi:10.1038/s41392-021-00712-2.
  • Hu B, Chan JF, Liu H, et al. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. Emerg Microbes Infect. 2022;11:2275–2287. doi:10.1080/22221751.2022.2117098.
  • Meng B, Abdullahi A, Ferreira I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–714. doi:10.1038/s41586-022-04474-x.
  • Liu Y, Hu G, Wang Y, et al. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. Proc Natl Acad Sci USA. 2021;118(12):e2025373118), doi:10.1073/pnas.2025373118.
  • Duan Q, Xia S, Jiao F, et al. A modified fibronectin type III domain-conjugated, long-acting pan-coronavirus fusion inhibitor with extended half-life. Viruses. 2022;14(4):655), doi:10.3390/v14040655.
  • Xia S, Zhu Y, Liu M, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020;17:765–767. doi:10.1038/s41423-020-0374-2.
  • Xia S, Lan Q, Zhu Y, et al. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct Target Ther. 2021;6:288), doi:10.1038/s41392-021-00712-2.
  • Sun X, Yi C, Zhu Y, et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat Microbiol. 2022;7:1063–1074. doi:10.1038/s41564-022-01155-3.
  • Xia S, Chan JF, Wang L, et al. Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 2022;32:404–406. doi:10.1038/s41422-022-00617-x.
  • Sheward DJ, Kim C, Fischbach J, et al. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. Lancet Infect Dis. 2022;22:1538–1540. doi:10.1016/S1473-3099(22)00663-6.
  • Xue S, Wang X, Wang L, et al. A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein. Cell Discov. 2022;8:88), doi:10.1038/s41421-022-00455-6.
  • Xing L, Xu X, Xu W, et al. A five-helix-based SARS-CoV-2 fusion inhibitor targeting heptad repeat 2 domain against SARS-CoV-2 and its variants of concern. Viruses. 2022: 14 (3):957.
  • Sun H, Li Y, Liu P, et al. Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Emerg Microbes Infect. 2020;9:1238–1241. doi:10.1080/22221751.2020.1770631.
  • Zhu Y, Hu Y, Liu N, et al. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides. Antiviral Res. 2022;208:105445), doi:10.1016/j.antiviral.2022.105445.
  • WHO. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
  • Saito A, Irie T, Suzuki R, et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 delta P681R mutation. Nature. 2022;602:300–306. doi:10.1038/s41586-021-04266-9.
  • Zhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. J Med Virol. 2022, doi:10.1002/jmv.28138.
  • Liu Z, Xu W, Xia S, et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020;5(1):282), doi:10.1038/s41392-020-00402-5.
  • Liu Z, Zhou J, Xu W, et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022;32:269–287. doi:10.1038/s41422-022-00612-2.
  • Xia S, Wen Z, Wang L, et al. Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (alpha). Cell Discov. 2021;7:109), doi:10.1038/s41421-021-00349-z.
  • Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–681. doi:10.1124/pr.58.3.10.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.